Yttrium Y 90 Glass Microspheres and Capecitabine in Treating Patients With Liver Cholangiocarcinoma or Liver Metastases

DISEASE CHARACTERISTICS: * Histologically confirmed diagnosis of 1 of the following: * Intrahepatic cholangiocarcinoma * Metastatic cancer confined to the liver * Measurable disease, defined as ≥ 1 lesion that can be accurately measured in ≥ 1 dimension as ≥ 20 mm by conventional techniques or as ≥ 10 mm by spiral CT scan * Must have tumor volume ≤ 50% of total liver volume based on visual estimation PATIENT CHARACTERISTICS: * ECOG performance status 0-2 * ANC ≥ 1,500/mm\^3 * Platelet count ≥ 75,000/mm\^3 * Serum creatinine ≤ 2.0 mg/dL * Serum bilirubin ≤ 1.5 times upper limit of normal * Albumin ≥ 2.0 g/dL * No baseline symptoms or laboratory values \> grade 2 in severity by NCI CTCAE v 3.0 criteria * Not pregnant or nursing * Fertile patients must use effective contraception * No malabsorption syndrome * No severe liver dysfunction or pulmonary insufficiency * No complete occlusion of the main portal vein * No contraindication to iodine-based contrast agents * No contraindication to hepatic artery catheterization (e.g., vascular abnormalities or bleeding diathesis) * No prior unanticipated severe reaction to fluoropyrimidine therapy, known hypersensitivity to fluorouracil, or known dihydropyrimidine dehydrogenase deficiency PRIOR CONCURRENT THERAPY: * No prior radiotherapy to the liver * No more than 2 prior therapies for metastatic disease to the liver * No prior intervention to or compromise of the Ampulla of Vater * At least 4 weeks since prior and no concurrent sorivudine or brivudine * No concurrent cimetidine